Instituto Ave Pulmo

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Idiopathic pulmonary fibrosis3 trials
• Asthma2 trials
• COPD2 trials

Phase

• Phase 24 trials
• Phase 33 trials

Status

• Completed3 trials
• Recruiting3 trials
• Terminated1 trial

Lead sponsor

• Boehringer Ingelheim1 trial
• Contineum Therapeutics1 trial
• Genentech, Inc.1 trial
• Hoffmann-La Roche1 trial
• Pfizer1 trial
• and 2 more

Running trials

• Recruiting

  Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis

  NCT07284459· Phase 2· Contineum Therapeutics· Source

  Contact: Nikki Nepomuceno

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma

  NCT06977581· Phase 2· Pfizer· Source

• Recruiting

  A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)

  NCT05878769· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Asthma1 recruiting
• COPD1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting

Closed trials

• Completed

  A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

  NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source